{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:57Z","timestamp":1707525117883},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,23]]},"DOI":"10.7759\/cureus.42316","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T08:31:22Z","timestamp":1690101082000},"source":"Crossref","is-referenced-by-count":0,"title":["Guillain-Barr\u00e9 Syndrome Following the Administration of Adenovirus Vector-Based COVID-19 Vaccine"],"prefix":"10.7759","author":[{"given":"Mardy L","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Miguel P","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 syndrome (GBS) following adenovirus vector COVID-19 vaccines. (2021). Accessed. August 5, 2021: https:\/\/www.who.int\/news\/item\/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs."},{"key":"ref2","article-title":"","year":"2021","unstructured":"COVID-19 Vaccine Safety Update. VAXZEVRIA, AstraZeneca AB. European Medicines Agency, Amsterdam; 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previo...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir960","article-title":"Recurrent Guillain-Barre syndrome following vaccination","volume":"54","author":"Baxter R","year":"2012","unstructured":"Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP. Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis. 2012, 54:800-4. 10.1093\/cid\/cir960","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon DA","year":"2013","unstructured":"Salmon DA, Proschan M, Forshee R, et al.. Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013, 381:1461. 10.1016\/S0140-6736(12)62189-8","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals P","year":"2012","unstructured":"De Wals P, Deceuninck G, Toth E, et al.. Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012, 308:175-81. 10.1001\/jama.2012.7342","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence","volume":"58","author":"Vellozzi C","year":"2014","unstructured":"Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014, 58:1149-55. 10.1093\/cid\/ciu005","journal-title":"Clin Infect Dis"},{"key":"ref7","unstructured":"Meeting Highlights From the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021. (2021). Accessed. August 5, 2021: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021."},{"key":"ref8","unstructured":"The Oxford\/AstraZeneca (ChAdOx1-S [Recombinant] Vaccine) COVID-19 Vaccine. What you need to know. (2021). Accessed: April 14, 2021: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know?gc...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01164-4","article-title":"Guillain-Barr\u00e9 syndrome associated with COVID-19 vaccines: a perspective from spontaneous report data","volume":"42","author":"Atzenhoffer M","year":"2022","unstructured":"Atzenhoffer M, Auffret M, Pegat A, Masmoudi K, Khouri C, Bertin B, Vial T. Guillain-Barr\u00e9 syndrome associated with COVID-19 vaccines: a perspective from spontaneous report data. Clin Drug Investig. 2022, 42:581-92. 10.1007\/s40261-022-01164-4","journal-title":"Clin Drug Investig"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.32598\/bcn.2021.3565.1","article-title":"Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients","volume":"12","author":"Karimi N","year":"2021","unstructured":"Karimi N, Boostani R, Fatehi F, et al.. Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients. Basic Clin Neurosci. 2021, 12:703-10. 10.32598\/bcn.2021.3565.1","journal-title":"Basic Clin Neurosci"},{"key":"ref11","article-title":"Guillain-Barre\u0301 syndrome after receiving Sputnik light COVID-19 vaccine: a case report from Palestine","volume":"4","year":"2022","unstructured":"Guillain-Barre\u0301 syndrome after receiving Sputnik light COVID-19 vaccine. a case report from Palestine. J Clin Stud Rev Rep. 2022, 4:1-3.","journal-title":"J Clin Stud Rev Rep"},{"key":"ref12","article-title":"Reports of Suspected Adverse Reaction to COVID-19 Vaccines (01 March to 11 April 2021)","year":"2021","unstructured":"Reports of Suspected Adverse Reaction to COVID-19 Vaccines. Food and Drug Administration, Muntinlupa, Philippines; 2021. https.\/\/www.fda.gov.ph\/wp-content\/uploads\/2021\/04\/Reports-of-Suspected-Adverse-Reaction-to-COVID-19-Vaccines-as-of-11...."},{"key":"ref13","unstructured":"FDA Requires a Warning about Guillain-Barr\u00e9 Syndrome (GBS) be Included in the Prescribing Information for Shingrix. (2021). Accessed. April 22, 2021: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-warning-about-guillain-barre-...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki N","year":"2012","unstructured":"Yuki N, Hartung HP. Guillain-Barr\u00e9 syndrome. N Engl J Med. 2012, 366:2294-304. 10.1056\/NEJMra1114525","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barr\u00e9 syndrome variant occurring after SARS-CoV-2 vaccination","volume":"90","author":"Allen CM","year":"2021","unstructured":"Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, Evans JR. Guillain-Barr\u00e9 syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021, 90:315-8. 10.1002\/ana.26144","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine","volume":"90","author":"Maramattom BV","year":"2021","unstructured":"Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, Mangat HS. Guillain-Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine. Ann Neurol. 2021, 90:312-4. 10.1002\/ana.26143","journal-title":"Ann Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/105257-guillain-barr-syndrome-following-the-administration-of-adenovirus-vector-based-covid-19-vaccine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:07Z","timestamp":1707508867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/105257-guillain-barr-syndrome-following-the-administration-of-adenovirus-vector-based-covid-19-vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.42316","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,23]]}}}